After delivery: How recipient cells shape the fate and function of transplanted mitochondria
- 1West China Hospital Sichuan University
Abstract
Background Mitochondrial transplantation is built on a simple idea: failing cells might be rescued by healthy mitochondria. The approach has entered early clinical testing, and encapsulation and cell‐type targeting have improved uptake in selected systems. Better delivery, however, does not explain the therapy. Main body Internalised donor mitochondria encounter an established network, quality‐control machinery and sensors for mitochondrial material. Donor material may remain in the endolysosomal system or reach the cytosol. Cytosolic fates include network integration, clearance and a candidate functional contribution without fusion. Intracellular processing may also generate bioactive cargo. These fates imply different mechanisms and evidence requirements. This Review examines how recipient cells shape the contribution of internalised mitochondria, while recognising extracellular routes to benefit. We distinguish direct transplantation evidence from mechanistic support drawn from endogenous mitochondrial biology and natural intercellular transfer. The required donor fate and duration depend on the therapeutic task. Transient rescue may rely on short‐term donor function or productive processing in specific models; sustained support may depend on continued donor function, recipient adaptation or redosing. Durable mitochondrial DNA (mtDNA) correction requires donor‐mtDNA retention and replication. Conclusions Linking these tasks to product design, safety assessment and clinical endpoints shifts the question from how many mitochondria enter cells to what they accomplish after arrival. Key points Recipient‐cell handling shapes what transplanted mitochondria do after uptake. Uptake, structural integration and donor mitochondrial DNA retention require distinct evidence. Transient rescue, sustained support and durable mitochondrial DNA correction impose different requirements. Therapeutic goals should guide donor selection, product testing and clinical endpoints.
Related
- Mitochondrial genome microhomology-mediated editing by donor DNA delivery into mitochondria in human cells
- A Novel Drp1-Golph2 Tether Mediates Mitochondria-Golgi Spatial Association to Orchestrate Mitochondrial Function and Hepatic Lipid Catabolism Across Vertebrates
- Mitochondria-Targeted OGG1 remodels Alveolar Epithelial Transitional States and Immune-Epithelial Communication after Chlorine Lung Injury
- Cardiomyocyte-specific deletion of thioredoxin promotes myocardial injury, infarction and mitochondrial dysfunction: translocation of cytosolic thioredoxin into mitochondria rescue myocardial dysfunction by restoration of cardiac mitochondrial structure and function.
- Rapsyn overexpression improves neuromuscular junction and skeletal muscle function after tourniquet-induced mouse hindlimb ischemia-reperfusion injuries
BibTeX
@article{zhang2026after,
title = {{After delivery: How recipient cells shape the fate and function of transplanted mitochondria}},
author = {Zhi‐Yuan Zhang and Bo‐Quan Qin and Shi‐Zhou Wu and Hui Zhang},
journal = {Clinical and translational medicine},
year = {2026},
month = oct,
doi = {10.1002/ctm2.70857},
url = {https://europepmc.org/article/PMC/PMC13655360},
note = {CC BY},
}
RIS
TY - JOUR
TI - After delivery: How recipient cells shape the fate and function of transplanted mitochondria
AU - Zhi‐Yuan Zhang
AU - Bo‐Quan Qin
AU - Shi‐Zhou Wu
AU - Hui Zhang
PY - 2026
DA - 2026/10/01
JO - Clinical and translational medicine
DO - 10.1002/ctm2.70857
UR - https://europepmc.org/article/PMC/PMC13655360
AB - Background Mitochondrial transplantation is built on a simple idea: failing cells might be rescued by healthy mitochondria. The approach has entered early clinical testing, and encapsulation and cell‐type targeting have improved uptake in selected systems. Better delivery, however, does not explain the therapy. Main body Internalised donor mitochondria encounter an established network, quality‐control machinery and sensors for mitochondrial material. Donor material may remain in the endolysosomal system or reach the cytosol. Cytosolic fates include network integration, clearance and a candidate functional contribution without fusion. Intracellular processing may also generate bioactive cargo. These fates imply different mechanisms and evidence requirements. This Review examines how recipient cells shape the contribution of internalised mitochondria, while recognising extracellular routes to benefit. We distinguish direct transplantation evidence from mechanistic support drawn from endogenous mitochondrial biology and natural intercellular transfer. The required donor fate and duration depend on the therapeutic task. Transient rescue may rely on short‐term donor function or productive processing in specific models; sustained support may depend on continued donor function, recipient adaptation or redosing. Durable mitochondrial DNA (mtDNA) correction requires donor‐mtDNA retention and replication. Conclusions Linking these tasks to product design, safety assessment and clinical endpoints shifts the question from how many mitochondria enter cells to what they accomplish after arrival. Key points Recipient‐cell handling shapes what transplanted mitochondria do after uptake. Uptake, structural integration and donor mitochondrial DNA retention require distinct evidence. Transient rescue, sustained support and durable mitochondrial DNA correction impose different requirements. Therapeutic goals should guide donor selection, product testing and clinical endpoints.
SN - 2001-1326
ER -